31st JSSX Annual Meeting (Matsumoto, 2016)



# 血液組織関門における 塩基性薬物吸排制御機構に関する研究

**Impact of Carrier-Mediated Transport of Cationic Drug and Nutrients at the Blood-Tissue Barrier** 

# 久保 義行 Yoshiyuki Kubo, PhD

# 富山大学大学院 医学薬学研究部(薬学) University of Toyama

## Acknowledgements

### University of Toyama (2011~present)

#### Ken-ichi Hosoya, Ph.D Shin-ichi Akanuma, Ph.D

Daisuke Ando, Ph.DHiroaki MiuraYasuyuki Kasai, Ph.DAyumi NakazawaEri Fukui-YamamotoAkiko ObataHideyuki HigashiGo OzekiTakanori HiguchiTatsuhiko SakuraiEikichi HisadaNarumi SekoYusuke KusagawaYoshimi ShimizuRyo MatsuyamaTatsuya SoutomeSatoshi MikiYuma Tega

Hiroaki MiuraAyaka TomiseAyumi NakazawaAi TsuchiyamaAkiko ObataTakuya UsuiGo OzekiTohru YaharaTatsuhiko SakuraiShizuka YahataNarumi SekoMasakazu YamamotoYoshimi ShimizuDiasuke YoneyamaTatsuya SoutomeChihiro YuzuriharaYuma TegaNobuyuki Zakoji

### Tohoku University (2010~2011)

Tetsuya Terasaki, Ph.D Sumio Ohtsuki, Ph.D (Kumamoto Univ.) Masanori Tachikawa, Ph.D Yasuo Uchida, Ph.D Students & Collaborators

#### Medical College of Georgia (2008~2010)

#### Vadivel Ganapathy, Ph.D (Texas Tech Univ.)

Seiji Miyauchi, Ph.D (Toho Univ.) Puttur D Prasad, Ph.D Muthusamy Thangaraju, Ph.D Students & Collaborators

#### Kanazawa University (2004~2008)

#### Akira Tsuji, Ph.D Yukio Kato, Ph.D

Ikumi Tamai, Ph.D Yoshimichi Sai, Ph.D Students & Collaborators

#### Osaka University (1998~2004)

#### Akihito Yamaguchi, Ph.D

Yoshinori Moriyama, Ph.D Satoshi Murakami, Ph.D (Tokyo Tech.) Tsuyoshi Nishi, Ph.D Shigeyuki Nada, Ph.D

#### Nagoya City University (1994~1998)

#### Harumi Okuyama, Ph.D (Kinjo Gakuin Univ.)

#### Support & Advise (2011~present)

<u>Teikyo University</u> Yoshiharu Deguchi, Ph.D Takashi Okura , Ph.D

University of Dublin Carsten Ehrhardt, Ph.D

<u>Keio University</u> Masatoshi Tomi, Ph.D Tomohiro Nishimura, Ph.D

## Acknowledgements



-3 mV \_\_\_\_\_0 mV

Kato et al. Pharm Res. 27:832-40 (2010)

#### Identification & KO mice analysis of mABCA5

Time (day)

Time (day)



#### Quantitative determination of membrane distributions of transporters



#### SLC transporters as therapeutic target for cancer



## **Retina** is essential for visual sense



Illustrate; Specialty Eye Care Medical Center

## **Diabetic retinopathy**



#### **Macular degeneration**

**Normal** 

#### Degenerated





http://www.kareiouhan.com/ Japanese ophthalmological Society & Wikipedia

## **Cationic neuroprotectants for retinal disease**

## Some cationic drugs express neuroprotective effect, and their utilities are expected in the treatment of retinal disease.

Retina

Angiogenesis

Choroid

Ischemia

Drugs	Effect
Imipramine	Neuroprotective
Desipramine	Neuroprotective
Memantine	Neuroprotective
Nipradilol	Neuroprotective
Timolol	Neuroprotective
Clonidine	Neuroprotective
Brimonidine	Neuroprotective
Propranolol	Anti-angiogenic
Pazopanib	Anti-angiogenic
Sorafenib	Anti-angiogenic

Mizuno et al. Invest Ophthalmol Vis Sci. 42:688–94. 2001 Arthur and Cantor. Exp Eye Res. 93:271–83. 2011 Lauterbach et al. J Neuropsychiatry Clin Neurosci. 22:8–18. 2010 Ristori et al. Invest Ophthalmol Vis Sci. 52:155–70. 2011

## **Cationic neuroprotectants for retinal disease**

## Some cationic drugs express neuroprotective effect, and their utilities are expected in the treatment of retinal disease.

Retina

-

Choroid

**\*** \*

Drugs	Effect
Imipramine	Neuroprotective
Desipramine	Neuroprotective
Memantine	Neuroprotective
Nipradilol	Neuroprotective
Timolol	Neuroprotective
Clonidine	Neuroprotective
Brimonidine	Neuroprotective
Propranolol	Anti-angiogenic
Pazopanib	Anti-angiogenic
Sorafenib	Anti-angiogenic

Mizuno et al. Invest Ophthalmol Vis Sci. 42:688–94. 2001 Arthur and Cantor. Exp Eye Res. 93:271–83. 2011 Lauterbach et al. J Neuropsychiatry Clin Neurosci. 22:8–18. 2010 Ristori et al. Invest Ophthalmol Vis Sci. 52:155–70. 2011

## Systemic drug delivery to retina



Kubo and Hosoya. Drug Delivery System. 27: 361-9 (2012)

## **Blood-retinal barrier (BRB)**

The carrier-mediated transport of nutrients has been studied at the inner BRB. However, little is known about the transport of cations at the BRB.



Kubo and Hosoya. Drug Delivery System. 27: 361-9 (2012)

## **Blood-retinal barrier (BRB)**

The carrier-mediated transport of nutrients has been studied at the inner BRB. However, little is known about the transport of cations at the BRB.



Kubo and Hosoya. Drug Delivery System. 27: 361-9 (2012)

## **Cationic drug transport systems at the BRB**

BUI (%)

## **Retinal uptake index (RUI)**

## Brain uptake index (BUI)





Comparison of the retinal (RUI) and brain uptake index (BUI) relationship in transporters and the lipophilicity trend line. The lipophilicity trend line indicates the correlation between the RUI and BUI and the log DC of the thirteen compounds. Blue and red circles are substrates for SLC transporters and P-gp, respectively. Each point represents the mean  $\pm$  SEM (n=3-6). L-Arg, L-arginine; L-Phe, L-phenylalanine; L-Leu, L-leucine; Gly, Glycine; T<sub>4</sub>, thyroxine.

Comparison of the initial uptake rate (V) and the *n*-octanol/Ringer distribution coefficient (DC) of compounds that cross the BRB by carrier-mediated transport. Uptake study was performed with an *in vitro* model cell line of inner BRB (TR-iBRB2 cells).

Kubo et al. J Pharm Sci. 102:3332-42 (2013) Hosoya et al. Pharm Res. 27:2715-24 (2010)

## **Cationic drug transport systems at the BRB**



Comparison of the retinal (RUI) and brain uptake index (BUI) relationship in transporters and the lipophilicity trend line. The lipophilicity trend line indicates the correlation between the RUI and BUI and the log DC of the thirteen compounds. Blue and red circles are substrates for SLC transporters and P-gp, respectively. Each point represents the mean  $\pm$  SEM (n = 3-6). L-Arg, L-arginine; L-Phe, L-phenylalanine; L-Leu, L-leucine; Gly, Glycine; T<sub>4</sub>, thyroxine.

Comparison of the initial uptake rate (V) and the *n*-octanol/Ringer distribution coefficient (DC) of compounds that cross the BRB by carrier-mediated transport. Uptake study was performed with an *in vitro* model cell line of inner BRB (TR-iBRB2 cells).

Kubo et al. J Pharm Sci. 102:3332-42 (2013) Hosoya et al. Pharm Res. 27:2715-24 (2010)

# **Carrier-mediated transport of [<sup>3</sup>H]verapamil**



# Inhibition study of [<sup>3</sup>H]verapamil uptake

#### **Cations and anions**

## Neuroprotectants



In the inhibition study, compounds were used at a concentration of 1 mM. MPP<sup>+</sup>, 1-methyl-4-phenylpyridinium; TEA, tetraethylammonium; PAH, *p*-aminohippuric acid. \*p < 0.01, significantly different from the control.

Kubo et al. Pharm Res. 30:847-56 (2013)

## Novel organic cation transporter is responsible

## Blood



## Cell

## Influx transport of cationic neuroprotectants



# **Carrier-mediated transport of [<sup>3</sup>H]clonidine**



Kubo et al. Mol Pharm. 11:3747-53 (2014)

## **Organic cation transport systems at the inner BRB**



Tega et al. J Pharm Sci. 104(3069-75 (2015), Kubo et al. J Pharm Sci. 102:3332-42 (2013), Kubo et al. Pharm Res. 30:847-56 (2013), Kubo et al. Mol Pharm. 11:3747-53 (2014)

## Influx transport of cationic nutrients



Kubo et al. Invest Ophthalmol Vis Sci. 56:5925-32 (2015), Kubo et al. Drug Metab Pharmacokinet. in press.

# Influx transport of cationic nutrients

## Immunohistochemical analysis of CAT1



1 (C<sub>1</sub>) (C<sub>2</sub>)

The rat retina was stained with anti-CAT1 antibodies and anti-GLUT1 antibodies (A). The colocalization of CAT1 and GLUT1 proteins was observed in the retinal capillary endothelial cells (B) and RPE cells (C). Scale bars, 50  $\mu$ m (A), 10  $\mu$ m (B) and 10  $\mu$ m (C).



## Knockdown analysis of **RFVTs**



Kubo et al. Invest Ophthalmol Vis Sci. 56:5925-32 (2015), Kubo et al. Drug Metab Pharmacokinet. in press.

## Efflux of 1-methyl-4-phenylpyridinium (MPP<sup>+</sup>)



## Elimination of [<sup>3</sup>H]MPP<sup>+</sup> across the BRB



Each value represents the mean  $\pm$  SEM (n = 3). \*p < 0.01, significantly difference from the value of [<sup>14</sup>C]D-mannitol.

## Elimination of [<sup>3</sup>H]spermine across the BRB

#### **Time-course**

#### Difference of $\lambda_2$ values



Each point represents the mean  $\pm$  S.E.M. (*n* = 5).

Each column represents the mean  $\pm$  S.E.M. (*n* = 5). \**p* < 0.01, significantly different from [<sup>14</sup>C]D-mannitol.

#### Kubo et al. Exp Eye Res. 124:17-23 (2014)

## Elimination of [<sup>3</sup>H]spermine across the BRB



Each point represents the mean  $\pm$  S.E.M. (*n* = 5).

Each column represents the mean  $\pm$  S.E.M. (*n* = 5). \**p* < 0.01, significantly different from [<sup>14</sup>C]D-mannitol.

Kubo et al. Exp Eye Res. 124:17-23 (2014)

## Carrier-mediated efflux of [<sup>3</sup>H]MPP<sup>+</sup> and [<sup>3</sup>H]spermine

#### [<sup>3</sup>H]MPP<sup>+</sup> transport [<sup>3</sup>H]Spermine transport MPP+ Retina Blood Blood Outer BRB Inner BRB Inner BRB Choroid MPP+ Retina Retina Spermine **Primary rat RPE cells TR-iBRB2** cells **TR-iBRB2** cells *K*<sub>m</sub> = 93 μM $K_m = 63 \ \mu M$ $K_{m1} = 0.968 \ \mu M$ 140-70-300- $K_{m2} = 158 \ \mu M$ Initial uptake rate [pmol/(min·mg protein)] 07 09 09 00 08 00 07 05 Initial uptake rate [pmol/(min·mg protein)] 60-50-50 l 6m uim)/lomd) 50 40-[S]/20 30-20-10 200 300 100 v 0 50 100 150 200 20 60 80 100 40 50 100 150 200 250 0 [MPP<sup>+</sup>] (µM) [MPP<sup>+</sup>] (µM) [Spermine] (µM)

Kubo et al. Exp Eye Res. 124:17-23 (2014)

## **Summary**



# Thank you for your attention.

Snow wall in Tateyama